According to filings with the U.S. Securities and Exchange Commission, ONL Therapeutics is raising up to $65,000,002.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, David Esposito played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About ONL Therapeutics
ONL Therapeutics (ONL) is a clinical-stage biopharmaceutical company committed to helping patients see the future. Our mission is to develop innovative therapeutics to protect and improve the vision of patients with a range of retinal disease and conditions. By advancing a breakthrough technology designed to prevent the death of key retinal cells caused by the activation of the natural Fas pathway, ONL is pioneering an entirely new approach to preserve sight. It is the first and only company focused on preventing Fas-mediated death of key retinal cells, which is a root cause of vision loss, a leading cause of blindness and an unaddressed medical need. ONLs lead therapeutic candidate, ONL1204, is a first-in-class small peptide Fas inhibitor designed to protect retinal cells from both death and inflammatory signaling pathways. ONL1204 Ophthalmic Solution is being developed for the treatment of retinal detachment, an acute condition for which the company has been granted orphan drug designation by the FDA. In addition, the company is currently developing ONL1204 in geographic atrophy associated with age-related macular degeneration, glaucoma, and other acute and chronic indications.

To learn more about ONL Therapeutics, visit http://www.onltherapeutics.com/
ONL Therapeutics Linkedin Page: https://www.linkedin.com/company/onl-therapeutics/

Contact:
David Esposito, Chief Executive Officer
734-412-8787
https://www.linkedin.com/in/davidesposito2/

SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.